The 42 references in paper N. Nenasheva M., Н. Ненашева М. (2014) “БЕЗОПАСНОСТЬ ИНГАЛЯЦИОННЫХ ГЛЮКОКОРТИКОСТЕРОИДОВ В ТЕРАПИИ БРОНХИАЛЬНОЙ АСТМЫ // SAFETY OF INHALED CORTICOSTEROIDS IN THE THERAPY OF BRONCHIAL ASTHMA” / spz:neicon:pulmonology:y:2014:i:3:p:113-120

1
Controlled trial of effects of cortisone acetate in status asthmaticus; report to the Medical Research Council by the subcommittee on clinical trials in asthma. Lancet. 1956; 271 (6947): 803–806.
(check this in PDF content)
2
Clark T.J.Effect of beclomethasone dipropionate delivered by aerosol in patients with asthma. Lancet. 1972; 1 (7765): 1361–1364.
(check this in PDF content)
3
Barnes P.J.Glucocorticosteroids: current and future directions. Br. J. Pharmacol. 2011; 163: 29–43.
(check this in PDF content)
4
Schacke H., Schottelius A., Docke W.D. et al.Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. USA. 2004; 101: 227–232.
(check this in PDF content)
5
Derendorf H., Nave R., Drollman A. et al.Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006; 28: 1042–1050.
(check this in PDF content)
6
Stoloff S.W., Kelly H.W. Updates on the use of inhaled corticosteroids in asthma. Curr. Opin. Allergy Clin. Immunol. 2011; 11 (4): 337–344.
(check this in PDF content)
7
Чучалин А.Г., Айсанов З.Р., Белевский А.С. и др.Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. Пульмонология. 2014; 2: 11–32. /Chuchalin A.G., Aysanov Z.R., Belevskiy A.S. et al.Federal guidelines for the diagnosis and treatment bronchial asthma. Pul'monologiya. 2014; 2: 11–32 (in Russian).
(check this in PDF content)
8
Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Crit. Care Med. 1998; 157: S1–S53.
(check this in PDF content)
9
Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy. 2006; 61: 518–526.
(check this in PDF content)
10
Roland N.J., Bhalla R.K., Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004; 126: 213–219.
(check this in PDF content)
11
Selroos O., Backman R., Forsen K.O. et al. Local side-effects during 4-year treatment with inhaled corticosteroids – a comparison between pressurized metered-dose inhalers and Turbuhaler. Allergy. 1994; 49: 888–890.
(check this in PDF content)
12
Rachelefsky G.S., Liao Y., Faruqi R.Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann. Allergy Asthma Immunol. 2007; 98 (3): 225–238.
(check this in PDF content)
13
Leach C.L., Davidson P.J., Hasselquist B.E., Boudreau R.J. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002; 122: 510–516.
(check this in PDF content)
14
Acerbi D., Brambilla G., Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm. Pharmacol. Ther. 2007; 20 (3): 290–303.
(check this in PDF content)
15
Huchon G., Magnussen H., Chuchalin A. et al.Lung function and asthma control with beclomethasone and formoterol in single inhaler. Respir. Med. 2009; 103: 41–49.
(check this in PDF content)
16
Gabrio B.J., Stein S.W., Velasquez D.J.A newmethod to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Intern. J. Pharm. 1999; 186 (1): 3–12.
(check this in PDF content)
17
Lavorini F., Fontana G.A.Targeting drugs to the airways: the role of spaser devices. Exp. Opin. Drug Deliv. 2009; 6 (1): 91–102.
(check this in PDF content)
18
Newman S.P., Weisz A.W., Talaee N., Clarke S.W. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991; 46: 712–716.
(check this in PDF content)
19
Ahmet A., Kim H., Spie S. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Clin. Immunol. 2011, 7: 13. DOI: 10.1186/1710-1492-7-13.
(check this in PDF content)
20
Buehring B., Viswanathan R., Binkley N., Busse W. Glucocorticoid-induced osteoporosis: An update on effects and management. J. Allergy Clin. Immunol. 2013; 132: 1019–1030.
(check this in PDF content)
21
Ferguson A.C., Van Bever H.P., Teper A.M. et al. A comparison of the relative growth velocities with budesonide and fluticasone propionate in children with asthma. Respir. Med. 2007; 101: 118–129.
(check this in PDF content)
22
Pedersen S., Warner J., Wahn U. et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics. 2002; 109: e92.
(check this in PDF content)
23
Sharek P.J., Bergman D.A. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics. 2000; 106: E8.
(check this in PDF content)
24
The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N. Engl. J. Med. 2000; 343: 1054–1063.
(check this in PDF content)
25
Kelly H.W., Nelson H.S. Potential adverse effects of the inhaled corticosteroids. Allergy Clin. Immunol. 2003; 112 (3): 469–478.
(check this in PDF content)
26
Lipworth B.J. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch. Intern. Med. 1999, 159: 941–955.
(check this in PDF content)
27
Bousquet J., Meziane H., Chanez P. et al. The response of two different dosages of beclometasone dipropionate suspension for nebulization versus a standard dose of beclometasone dipropionate via a metered-dose inhaler on bronchoprovocation testing in adults with asthma. Respir. Med. 2003; 97 (Suppl. B): S11–S14.
(check this in PDF content)
28
Thompson P.J., Davies R.J., Young W.F. et al. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir. Med. 1998; 92 (Suppl. A): 33–39.
(check this in PDF content)
29
Bousquet J., Poli G., Acerbi D. et al. Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate / formoterol fixed combination. Clin. Pharmacokinet. 2009; 48 (6): 347–358.
(check this in PDF content)
30
Kelly H.W. Comparison of inhaled corticosteroids: An update. Ann. Pharmacother. 2009; 43 (3): 519–527.
(check this in PDF content)
31
Jones A., Fay J.K., Burr M. et al. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2002; (1): CD003537.
(check this in PDF content)
32
Packe G.E., Douglas J.G., McDonald A.F. et al.Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax. 1992; 47: 414–417.
(check this in PDF content)
33
Wong C.A., Walsh L.J., Smith C.J. et al.Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 2000; 355: 1399–1403.
(check this in PDF content)
34
Agertoft L., Pedersen S.Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N. Engl. J. Med. 2000; 343: 1064–1069.
(check this in PDF content)
35
Agertoft L., Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J. Allergy Clin. Immunol. 2005; 115: 940–945.
(check this in PDF content)
36
Kelly H.W., Sternberg A.L., Lescher R. et al. Effect of inhaled glucocorticoids in childhood on adult height. N. Engl. J. Med. 2012; 367: 904–912.
(check this in PDF content)
37
Chauhan B.F., Chartrand C., Ducharme F.M.Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst. Rev. 2013; (2): CD009611.
(check this in PDF content)
38
Cumming R., Mitchell P., Leeder S. Use of inhaled corticosteroids and the risk of cataracts. N. Engl. J. Med. 1997; 337: 8–14.
(check this in PDF content)
39
Garbe E., LeLorier J., Boivin J., Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. J.A.M.A. 1997; 277: 722–727.
(check this in PDF content)
40
Mak V., Melchor R., Spiro S. Easy bruising as a side-effect of inhaled corticosteroids. Eur. Respir. J. 1992; 5: 1068–1074.
(check this in PDF content)
41
Autio P., Karjalainen J., Risteli L. et al. Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. Am. J. Respir. Crit. Care Med. 1996; 153: 1172–1175.
(check this in PDF content)
42
Dahl R.Systemic side effects of inhaled corticosteroids in patients with asthma. Respir. Med. 2006; 100 (8): 1307–1317. Информация об авторе Ненашева Наталья Михайловна – д. м. н., профессор кафедры клинической аллергологии ГБОУ ДПО РМАПО; тел.: (499) 196-19-54; e-mail:
(check this in PDF content)